Skip to main content
OpenTrials
Completed

NCT Number: NCT02042716

Added Value of Supersonic Shear Imaging in the Diagnosis of White Matter Damage in Preterm Infants

Preterm birth and perinatal events related can interrupt microscopic maturation of the developing white matter leading to diffuse injury and subsequent neurocognitive impairments. Brain maturation can be studied using diffusion tensor imaging but is difficult to assess early after birth, repeatedly and at the bedside. Supersonic Shear wave Imaging (SSI) could be of interest in this clinical setting. This technique, already investigated in adults (breast, thyroid or liver fibrosis staging), has not been yet evaluated in neonates.

Objective:

To describe the feasibility and reproducibility of quantitative elasticity mapping in preterm infants and to correlate to gestational age.

Methods:

SSI is a quantitative stiffness imaging technique based on the combination of a remote palpation induced into tissues by the radiation force a focused ultrasonic beam and an ultrafast ultrasound imaging sequence. Such ultrafast frame rates permit to track in real time the displacements induced by the propagation of the resulting shear waves. For each pixel, the shear wave speed can be estimated locally and enables quantitative mapping of the local shear elasticity (characterizing the stiffness in kPa). In this study, we will use a new generation of ultrafast ultrasound scanners (Aixplorer®, Supersonic Imagine, Aix en Provence, France) with a linear L10-2 probe (256 elements, 6 MHz) in neonates born between 25 and 40 weeks' gestation (n=100). Three separate acquisitions will be obtained for each area of interest both on right and left sides and stiffness was measured using a unique ROI of 2.5 cm².

Completed

Looking for future studies?

Notify Me

Key information

Age range

24 week–40 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Robert Debré

Paris, 75019, France

About this study

White matter damage occurs in 20% of preterm infants in industrialized countries. These lesions are difficult to evaluate by standard ultrasound. The quantitative elastography is a new medical imaging technique and potentially a diagnostic tool in brain lesions in preterm infants. Shear wave Imaging (SSI) could be of interest in this clinical setting. This technique, already investigated in adults (breast, thyroid or liver fibrosis staging), has not been yet evaluated in neonates.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • gestational age between 24 +0 and 31 +6 j GA) and 39 +0 and 40 +6 d (control group)
  • Inborn or Outborn
  • Informed consent of the holders of the exercise of parental authority
  • recipient of a social security system (excluding AME) Child

Exclusion criteria

  • Malformation known pathology;
  • Known chromosomal abnormality;

Treatment and study plan

diagnosis of white matter damage in preterm infants

Other

Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants

Primary outcomes

  1. Sequences quantitative elastography and ultra-sensitive Doppler ultrasound performed on AixplorerTM (V2) data of brain MRI preterm infants.

    Time frame: Up to on 40GA + /-1week fo preterm infants<32GA. For newborns at term:on day3+-1d

    To describe the feasibility and reproducibility of quantitative elasticity mapping in preterm infants and to correlate to gestational age

    • For preterm infants <32GA: Quantitative elasticity mapping will be repeated at different stages of postnatal development of preterm infants: on day0-day1, day3 + /-1d, day8, day21 + /-1d; 40GA + /-1week.
    • For newborns at term (39-40GA +6 d) : Quantitative elasticity mapping will be performed on day3+-1

Secondary outcomes

  1. Correlation and comparison of measures elastography MRI to determine the prognosis of brain abnormalities detected by elastography

    Time frame: For preterm infants <32GA:up to 40GA+/-1 week.For newborns at term :on day3+-1

    Longitudinal comparison of measures of quantitative elastography in the supratentorial white matter, corpus callosum, gray matter (basal ganglia) and white matter infratentorial (cerebellar hemispheres) during development in preterm infants <32 weeks and compared the values obtained in the newborn term.

    For preterm infants <32GA:on day0-day1, day3 + /-1d, day8, day21 + /-1d; 40GA + /-1week.For newborns at term :on day3+-1

  2. Quantitative cerebral perfusion values obtained by Doppler ultra-sensitive

    Time frame: up to 40GA + /-1week for preterm infants <32GA .For newborns at term :on day3+-1

    Quantitative cerebral perfusion values obtained by Doppler ultra-sensitive (with standard setting speeds) in premature infants with and without white matter lesions in the frontal white matter and basal ganglia (temporal curve of blood flow in the region interest with defined and standardized measurement of peak systolic and diastolic values: pulsatility index.

  3. Cerebral perfusion values obtained by Doppler ultra-sensitive

    Time frame: on day21 + /-1d

    Cerebral perfusion values obtained by ultra-sensitive Doppler in premature infants with abnormal EEG characterized (positive rolandic spikes> 2 min, convulsions ...) during the first 21 days of life.

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: BELUGA

Important dates

Study start
2013
Primary completion
2019
Study completion
2019
First posted
Jan 23, 2014
Registry last updated
Apr 17, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.